Ardelyx (ARDX) Q3 2024 earnings summary

Executive summary

• Q3 2024 total revenue reached $98.2 million, up from $56.4 million in Q3 2023, driven by strong product sales of IBSRELA and XPHOZAH.

• IBSRELA net product sales were $40.6 million, nearly double year-over-year and up 15% sequentially; XPHOZAH net product sales were $51.5 million, up 39% sequentially.

• Net loss for Q3 2024 was $0.8 million, or less than a penny per share, compared to net income of $6.6 million in Q3 2023, reflecting higher operating expenses.

• Cash, cash equivalents, and short-term investments totaled $190.4 million at quarter end, with a pro forma cash balance over $240 million after a $50 million debt draw.

• The company is actively addressing Medicare coverage uncertainty for XPHOZAH through legislative, legal, and commercial strategies.

Financial highlights

• Q3 2024 total revenue was $98.2 million, up 74% year-over-year; nine-month revenue was $217.5 million, up 141%.

• Q3 2024 product sales: IBSRELA $40.6 million, XPHOZAH $51.5 million; nine-month sales: IBSRELA $104.4 million, XPHOZAH $103.7 million.

• Cost of goods sold for Q3 2024 was $15.7 million, up 104% year-over-year; operating expenses were $80.3 million, up 94%.

• R&D expenses were $15.3 million, and SG&A expenses were $65.0 million for Q3 2024.

• Gross margin for Q3 2024 was approximately 84%.

Outlook and guidance

• Full-year 2024 IBSRELA U.S. net product sales guidance narrowed to $145–$150 million.

• Continued top-line growth expected in Q4 for both products.

• Guidance for 2025 IBSRELA sales will be provided early next year; XPHOZAH guidance timing remains uncertain due to Medicare policy changes.

• Available cash and investments are expected to fund operations for at least one year from September 30, 2024.

• Management expects continued operating losses as commercialization and development investments continue.